Market revenue in 2023 | USD 1,843.3 million |
Market revenue in 2030 | USD 2,485.6 million |
Growth rate | 4.4% (CAGR from 2023 to 2030) |
Largest segment | Stimulants |
Fastest growing segment | Non-stimulants |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stimulants, Non-stimulants |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.94% in 2023. Horizon Databook has segmented the Europe attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
The rising prevalence of ADHD among children and adults is the major factor expected to drive the market over the forecast period. Key market players in this region are developing and commercializing new drugs, which is expected to further contribute to market growth. In recent years, the European Commission approved several drugs for ADHD care in the region, including INTUNIV.
On the other hand, key factors driving this market include government recommendations for ADHD treatment, growing R&D expenditure, and supportive regulatory policies. In Europe, dexamphetamine and methylphenidate are recommended as first-line treatment options for adult ADHD.
For example, lisdexamfetamine (LDX) has been introduced as a slow-release formulation of dexamphetamine. In countries such as the UK, Norway, Sweden, Switzerland, Netherlands, Ireland, and Denmark, ADHD medicines such as Elvanse, Strattera, and Medikinet are prescribed with full-time licenses, and off-label prescription is promoted by national guidelines.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe attention deficit hyperactivity disorder market , including forecasts for subscribers. This continent databook contains high-level insights into Europe attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account